2025 AMCP Nexus Congress

BioCryst will attend the 2025 AMCP Nexus Congress from Oct 27-30, 2025.

  • Burden of Treatment for Pediatric Patients (Aged Less Than 12 Years) With Hereditary Angioedema and Their Caregivers
    HAEA National Summit | 2025 | Hereditary Angioedema (HAE)
  • Patient Perspectives on the Importance of HAE Treatments
    HAEA National Summit | 2025 | Hereditary Angioedema (HAE)
  • HAE Attack Rates in Pediatric Patients 2 to <12 Years of Age with Prophylactic Berotralstat: Results from Interim Analysis of APeX-P
    HAEA National Summit | 2025 | Hereditary Angioedema (HAE)
  • Berotralstat Use Reduced Number of HAE Attacks Requiring Treatment or Professional Care in Pediatric Patients: Interim Results From APeX-P
    EAACI | 2025 | Hereditary Angioedema (HAE)
  • Assessment of the Effectiveness and Tolerability of Berotralstat for Long-term Prophylaxis in Hereditary Angioedema: Findings from the Berolife Study
    EAACI | 2025 | Hereditary Angioedema (HAE)

Have questions about any of our medicines that are currently approved or in development, or would you like to request to be connected with an MSL?

Have questions about our company?